# Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia

> **NCT05316493** · PHASE2,PHASE3 · RECRUITING · sponsor: **Xiaojun Chen** · enrollment: 172 (estimated)

## Conditions studied

- Atypical Endometrial Hyperplasia
- Fertility Issues
- Overweight and Obesity

## Interventions

- **BEHAVIORAL:** Intensive Lifestyle Intervention (ILI)
- **DRUG:** Megestrol Acetate 160 MG Oral Tablet
- **DRUG:** Levonorgestrel-Releasing Intrauterine Contraceptive System (Mirena), 52 Mg

## Key facts

- **NCT ID:** NCT05316493
- **Lead sponsor:** Xiaojun Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-13
- **Primary completion:** 2026-02-28
- **Final completion:** 2027-02-28
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05316493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05316493, "Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05316493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*